Redeye lowers its forecasts for Q1 while leaving the rest of 2024 roughly unchanged. While we expect a soft Q1 due to adverse weather conditions, we believe the current valuation implies low expectations on growth and margins mid-term.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

© Modular Finance, source Nordic Press Releases